| Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. | |
| | |
MedLine Citation:
|
PMID: 18811891 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite the introduction of new drugs that have changed the course of pulmonary arterial hypertension (PAH), some patients are still refractory to treatment and deteriorate rapidly. Long-acting phosphodiesterase-5 inhibitors are a new class of drugs that are effective in PAH. This prospective study assessed the potential of combination therapy with prostacyclin and tadalafil for treatment of severe PAH. We report four cases of severe PAH that deteriorated despite prostacyclin therapy. Two patients had Eisenmenger syndrome, one had pulmonary hypertension associated with scleroderma and one had histiocytosis X. All were treated with tadalafil, 10-20 mg once daily, in addition to prostacyclin. After 3 months of treatment, all patients improved clinically, with an increase in mean 6MWD from 214 to 272 m. In three patients, the New York Heart Association functional class decreased from IV to III. Echocardiograms showed no significant changes in pulmonary arterial pressure. Although this study was limited by the small sample size, it suggests that tadalafil in combination with prostacyclin is an effective treatment for severe PAH. Tadalafil may be beneficial for the treatment of patients with advanced disease. |
| | |
Authors:
|
Daniele Bendayan; David Shitrit; Mordechai R Kramer |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Respirology (Carlton, Vic.) Volume: 13 ISSN: 1440-1843 ISO Abbreviation: Respirology Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-09-24 Completed Date: 2009-02-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9616368 Medline TA: Respirology Country: Australia |
Other Details:
|
Languages: eng Pagination: 916-8 Citation Subset: IM |
Affiliation:
|
Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antihypertensive Agents / therapeutic use* Carbolines / therapeutic use* Drug Therapy, Combination Eisenmenger Complex / complications Epoprostenol / therapeutic use* Female Humans Hypertension, Pulmonary / drug therapy*, etiology Middle Aged Phosphodiesterase Inhibitors / therapeutic use* Pilot Projects Prospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil; 35121-78-9/Epoprostenol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical characteristics and efficacy of bronchoscopic intervention for tracheobronchial leiomyoma.
Next Document: Pulmonary hypertension responding to hyperthyroidism treatment.